References
- Atkin SD, Abid S, Foster M, Bose M, Keller A, Hollaway R, Sader HS, Greenberg DE, Finklea JD, Castanheira M, et al. Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime-avibactam. Infect Drug Resist. 2018;11:1499–1510. https://doi.org/10.2147/IDR.S173804
- Blanchard AC, Waters VJ. Microbiology of cystic fibrosis airway disease. Semin Respir Crit Care Med. 2019;40(6):727–736. https://doi.org/10.1055/s-0039-1698464
- Care for people with cystic fibrosis in Poland. Current status and recommendations for improvement. Report. Warsaw-Cracov (Poland): Care for People with Cystic Fibrosis in Poland; 2019 [cited 2024 Oct 09]. Available from https://ptwm.org.pl/assets/file/501,raport_druk.pdf
- Caverly LJ, VanDevanter DR. The elusive role of airway infection in cystic fibrosis exacerbation. J Pediatric Infect Dis Soc. 2022;11(Supplement_2):S40-s45. https://doi.org/10.1093/jpids/piac062
- Chalmers JD, Moffitt KL, Suarez-Cuartin G, Sibila O, Finch S, Furrie E, Dicker A, Wrobel K, Elborn JS, Walker B, et al. Neutrophil elastase activity is associated with exacerbations and lung function decline in bronchiectasis. Am J Respir Crit Care Med. 2017;195(10):1384–1393. https://doi.org/10.1164/rc-cm.201605-1027OC
- Davis CP. Normal flora. In: Baron S, ed. Medical Microbiology. 4th ed. Galveston (TX): University of Texas Medical Branch at Galveston; 1996.
- Fischer AJ, Singh SB, LaMarche MM, Maakestad LJ, Kienenberger ZE, Pena TA, Stoltz DA, Limoli DH. Sustained coinfections with Staphylococcus aureus and Pseudomonas aeruginosa in Cystic Fibrosis. Am J Respir Crit Care Med. 2021;203(3):328–338. https://doi.org/10.1164/rccm.202004-1322OC
- Goss CH, Mayer-Hamblett N, Aitken ML, Rubenfeld GD, Ramsey BW. Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis. Thorax. 2004;59(11):955-959. https://doi.org/10.1136/thx.2003.017707
- Høiby N, Ciofu O, Bjarnsholt T. Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiol. 2010;5(11):1663–1674. https://doi.org/10.2217/fmb.10.125
- Kesimer M, Ford AA, Ceppe A, Radicioni G, Cao R, Davis CW, Doerschuk CM, Alexis NE, Anderson WH, Henderson AG, et al. Airway mucin concentration as a marker of chronic bronchitis. N Engl J Med. 2017;377(10):911–922. https://doi.org/10.1056/NEJ-Moa1701632
- Lo DK, Muhlebach MS, Smyth AR. Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis. Cochrane Database Syst Rev. 2022;12(12):Cd009650. https://doi.org/10.1002/14651858.CD009650.pub5
- Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. Clin Microbiol Rev. 2002;15(2):194–222. https://doi.org/10.1128/CMR.15.2.194-222.2002
- Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268-281. https://doi.org/10.1111/j.1469-0691.2011.03570.x
- Marsac C, Berdah L, Thouvenin G, Sermet-Gaudelus I, Corvol H. Achromobacter xylosoxidans airway infection is associated with lung disease severity in children with cystic fibrosis. ERJ Open Res. 2021;7(2). https://doi.org/10.1183/23120541.00076-2021
- Menetrey Q, Dupont C, Chiron R, Jumas-Bilak E, Marchandin H. High occurrence of bacterial competition among clinically documented opportunistic pathogens including Achromobacter xylosoxidans in cystic fibrosis. Front Microbiol. 2020;11:558160. https://doi.org/10.3389/fmicb.2020.558160
- Milczewska J, Syunyaeva Z, Żabińska-Jaroń A, Sands D, Thee S. Changing profile of bacterial infection and microbiome in cystic fibrosis: when to use antibiotics in the era of CF-TR-modulator therapy. Eur Respir Rev. 2024;33(174). https://doi.org/10.1183/16000617.0068-2024
- Naseem R, Howe N, Williams CJ, Pretorius S, Green K. What diagnostic tests are available for respiratory infections or pulmonary exacerbations in cystic fibrosis: a scoping literature review. Respir Investig. 2024;62(5):817–831. https://doi.org/10.1016/j.resinv.2024.07.005
- Nolan PJ, Jain R, Cohen L, Finklea JD, Smith TT. In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against Pseudomonas aeruginosa isolated from patients with cystic fibrosis. Diagn Microbiol Infect Dis. 2021;99(2):115204.
- Pang Z, Raudonis R, Glick BR, Lin TJ, Cheng Z. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnol Adv. 2019;37(1):177–192. https://doi.org/10.1016/j.diagmicrobio.2020.115204
- Perikleous EP, Gkentzi D, Bertzouanis A, Paraskakis E, Sovtic A, Fouzas S. Antibiotic resistance in patients with cystic fibrosis: past, present, and future. Antibiotics (Basel). 2023;12(2). https://doi.org/10.3390/antibiotics12020217
- Sands D, Milczewska J, Walicka-Serzysko K, Pogorzelski A, Cofta S, Skorupa W. Respiratory tract infections in cystic fibrosis. Forum Zakazen (PL). 2021;12:163–173
- Smyth AR, Bell SC, Bojcin S, Bryon M, Duff A, Flume P, Kashirskaya N, Munck A, Ratjen F, Schwarzenberg SJ, et al. European Cystic Fibrosis Society Standards of Care: Best practice guidelines. J Cyst Fibros. 2014;13 Suppl 1:S23–42. https://doi.org/10.1016/j.jcf.2014.03.010
- Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–327. https://doi.org/10.1016/S1473-3099(17)30753-3
- Turcios NL. Cystic fibrosis lung disease: An overview. Respir Care 2020;65(2):233–251. https://doi.org/10.4187/respcare.06697
- Valenza G, Tappe D, Turnwald D, Frosch M, König C, Hebestreit H, Abele-Horn M. Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. J Cyst Fibros. 2008;7(2):123–127. https://doi.org/10.1016/j. jcf.2007.06.006
- Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, Meyer KC, Birrer P, Bellon G, Berger J, Weiss T, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest. 2002;109(3):317–325. https://doi.org/10.1172/JCI13870
- Zolin A, Orenti A, Jung A, van Rens J, et al. ECFSPR Annual Report 2021. Karup (Denmark): European Cystic Fibrosis Society; 2023.